SCHEMBL347455

SCHEMBL347455

C[n+]1c(/C=C2\C=CN(CCCCCC(=O)O)c3ccccc32)sc2ccccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.41
MEN1 O00255 5/20 0.41
KMT2A Q03164 5/20 0.41
HTT P42858 4/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
TDP1 Q9NUW8 3/20 0.41
THRB P10828 2/20 0.41
MAPK1 P28482 2/20 0.41
ALDH1A1 P00352 4/20 0.36
NPSR1 Q6W5P4 3/20 0.36
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
MCL1 Q07820 2/20 0.36
POLB P06746 2/20 0.36
KDM4E B2RXH2 2/20 0.36
BLM P54132 1/20 0.36
CTDSP1 Q9GZU7 2/20 0.35
DUSP3 P51452 1/20 0.35
NLRP3 Q96P20 1/20 0.35
CYP2D6 P10635 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11949226 1.00 MAPT (0.41) MAPTMEN1KMT2AHTTSMN1; SMN2
SCHEMBL13646003 0.93 MAPT (0.41) MAPTMEN1KMT2AHTTSMN1; SMN2
SCHEMBL13205886 0.90 MAPT (0.39) MAPTMEN1KMT2AHTTSMN1; SMN2
SCHEMBL20176262 0.89 MAPT (0.37) MAPTMEN1KMT2AHTTSMN1; SMN2
SCHEMBL347151 0.89 HTT (0.38) MAPTMEN1KMT2AHTTSMN1; SMN2
SCHEMBL13205924 0.88 MAPT (0.38) MAPTMEN1KMT2AHTTSMN1; SMN2
SCHEMBL12994306 0.87 MAPT (0.51) MAPTMEN1KMT2AHTTSMN1; SMN2
SCHEMBL13205887 0.87 HTT (0.41) MAPTMEN1KMT2AHTTSMN1; SMN2
SCHEMBL10029641 0.87 HTT (0.37) MAPTMEN1KMT2AHTTSMN1; SMN2
SCHEMBL14596244 0.86 INSR (0.39) MAPTMEN1KMT2AHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9670476-B2 Enzyme substrate comprising a functional dye and associated technology and methods BIOTIUM, INC. (US) 2017-06-06 US disclosed
US-9580749-B2 Dyes and labeled molecules BIOTIUM, INC. (US) 2017-02-28 US disclosed
US-20160237421-A9 ENZYME SUBSTRATE COMPRISING A FUNCTIONAL DYE AND ASSOCIATED TECHNOLOGY AND METHODS BIOTIUM, INC. (US) 2016-08-18 US disclosed
US-9102835-B2 Methods of using dyes in association with nucleic acid staining or detection and associated technology BIOTIUM, INC. (US) 2015-08-11 US disclosed
US-20140273151-A1 ENZYME SUBSTRATE COMPRISING A FUNCTIONAL DYE AND ASSOCIATED TECHNOLOGY AND METHODS BIOTIUM, INC. (US) 2014-09-18 US disclosed
US-8778627-B2 Enzyme substrate comprising a functional dye and associated technology and methods BIOTIUM, INC. (US) 2014-07-15 US disclosed
US-8753814-B2 Methods of using dyes in association with nucleic acid staining or detection and associated technology BIOTIUM, INC. (US) 2014-06-17 US disclosed
US-20140106349-A1 Dyes and Labeled Molecules ALLELOGIC BIOSCIENCES CORPORATION (US) 2014-04-17 US disclosed
US-20140073058-A1 Methods of Using Dyes in Association with Nucleic Acid Staining or Detection and Associated Technology BIOTIUM, INC. (US) 2014-03-13 US disclosed
US-8586325-B2 Enzyme substrate comprising a functional dye and associated technology and methods BIOTIUM, INC. (US) 2013-11-19 US disclosed
US-8232050-B2 Methods of using dyes in association with nucleic acid staining or detection and associated technology BIOTIUM, INC. (US) 2012-07-31 US disclosed
US-20120115129-A1 ENZYME SUBSTRATE COMPRISING A FUNCTIONAL DYE AND ASSOCIATED TECHNOLOGY AND METHODS BIOTIUM, INC. (US) 2012-05-10 US disclosed
EP-2428586-A1 Dimeric and trimeric nucleic acid dyes, and associated systems and methods Biotium Inc. (US) 2012-03-14 EP disclosed
US-20100323453-A1 Methods of Using Dyes in Association with Nucleic Acid Staining or Detection and Associated Technology BIOTIUM, INC. (US) 2010-12-23 US disclosed
US-20100317016-A1 DYES AND LABELED MOLECULES BIOTIUM, INC. (US) 2010-12-16 US disclosed
US-7803943-B2 Methods of using dyes in association with nucleic acid staining or detection and associated technology BIOTIUM, INC. (US) 2010-09-28 US disclosed
US-7776567-B2 Dimeric and trimeric nucleic acid dyes, and associated systems and methods BIOTIUM, INC. (US) 2010-08-17 US disclosed
US-20100009454-A1 METHODS OF USING DYES IN ASSOCIATION WITH NUCLEIC ACID STAINING OR DETECTION AND ASSOCIATED TECHNOLOGY BIOTIUM, INC. 2010-01-14 US disclosed
US-7601498-B2 Methods of using dyes in association with nucleic acid staining or detection and associated technology BIOTIUM, INC. (US) 2009-10-13 US disclosed
WO-2007100392-A2 ENZYME SUBSTRATE COMPRISING A FUNCTIONAL DYE AND ASSOCIATED TECHNOLOGY AND METHODS BIOTIUM, INC. (US) 2007-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115129-A1 ENZYME SUBSTRATE COMPRISING A FUNCTIONAL DYE AND ASSOCIATED TECHNOLOGY AND METHODS ENGASE, GBA3, HSD17B14 MAPT 2600/4885MEN1 2545/4885KMT2A 3358/4885
US-20100317016-A1 DYES AND LABELED MOLECULES DNA2, POLL, POLRMT MAPT 2935/4885MEN1 3095/4885KMT2A 4166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.